Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-04-11
2006-04-11
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S597000, C514S422000, C548S311400, C548S341500, C548S342500, C546S336000, C564S050000, C544S362000
Reexamination Certificate
active
07026357
ABSTRACT:
Compound of formula (I):and medicinal products containing the same are useful as dual α2/5-HT2cantagonist receptors.
REFERENCES:
Robert Aslanian et al., Identification of a Novel, Orally Bioavailable Histamine H3 Receptor Antagonist Based on the 4-Benzyl-(1H-imidazol-4-yl)Template, Bioorganic & Medicinal Chemistry Letters 12(2002) 937-941.
Christine-Brefel-Courbon et al., alpha-2 Adrenoceptor Antagonists, A New Approach to Parkinson's Disease, Drug Therapy, CNS Drugs 1998 Sep.: 10(3).
Gaster et al., Latest Developments in Serotonin Receptor Modulation, Annual Reports in Medicinal Chemistry.
Clark, et al.,Neuroendocrinology, 41: 36-43 (1985).
Reid, et al.,Lancetpp. 421-423 Aug. 22, (1987).
Smith, et al.,Physiology&Behavior, 41: 7-14 (1987).
Bitran, et al.,Neuroscience&Biobehavioral Reviews, 11: 365-389 (1987).
Danjou, et al.,B J Clin Pharmac, 26: 733-739 (1988).
Susset, et al.,J Urology, 141: 1360-1363 (1989).
Riley et al.,Sexual and Marital Therapy, 4:17-26 (1989).
Koskinen, et al.,Physiology&Behavior, 50: 589-593 (1991).
Jacobsen, et al.,J. Clin Psychiatry, 53:119-122 (1992).
Montorsi, et al.,Urology, 44(5): 732-736 (1994).
Carey, et al.,Archives of Sexual Behavior, 25(4): 341-360 (1996).
Vogt, et al.,Intl J Impotence Res, 9: 155-161 (1997).
Kunelius, et al.,Urology, 49(3): 441-444 (1997).
Morales, et al.,Intl J Impotence Res, 12(S1): S70-S74 (2000).
Goldstein, et al.,Intl J Impotence Res, 12(S1): S75-S80 (2000).
Goldstein, et al.,World J Urology, 19: 51-56 (2001).
Foreman, et al.,Life Sciences, 45(14): 1263-1270 (1989).
Watson, et al.,Pharmacology Biochemistry&Behavior, 39: 605-612 (1991).
Klint, et al.,Psychopharmacology, 119: 291-294 (1995).
Popova, et al.,Neuroendocrinology76: 28-34 (2002).
O'Neill, et al.,Pharmacology Biochemistry&Behavior, 63(2): 237-243 (1999).
Kettle, et al.,British J Pharmacology, 126: 572-574 (1999).
Herrick-Davis, et al.,J Pharmacology&Exp Therapeutics, 295(1):226-232 (2000).
Wood, et al.,Drug Dev Res, 54: 88-94 (2001).
Sodhi, et al.,Molecular Psychiatry, 6: 373-379 (2001).
Abi-Saab, et al.,Psychopharmacology, 162: 55-62 (2002).
Hertel, et al.,Science, 286: 105-107 (1999).
Litman, et al.,British J Psychiatry, 168:571-579 (1996).
Sara, et al.,Behavioral and Neural Biology, 51: 401-411 (1989).
Smith, et al.,J Psychopharmacology, 6(3):376-381 (1992).
Coull, et al.,Psychopharmacology, 123: 239-249 (1996).
Pascual, et al.,Neuroscience Letters, 142: 36-40 (1992).
Tellez, et al.,Eur J Pharmacology, 277: 113-116 (1995).
Sirvio, et al.,Pharmacology Biochem&Behavior, 45: 123-129 (1993).
Haapalinna, et al.,Eur J Pharmacology, 347: 29-40 (1998).
Chopin, et al.,J Pharmacology&Exp Therapeutics, 301(1): 187-196.
Paiva, et al.,Psychopharmacology, 96:395-399 (1988).
Landolt, et al.,Neuropsychopharmacology, 21:455-466 (1999).
Sharpley, et al.,Biological Psychiatry, 47:468-470 (2000).
Smith, et al.,Pharmacological Biochemistry and Behavior, 71:599-605 (2002).
Advanced Organic Chemistry, IV Ed, John Wiley & Sons, New York (1992).
Berendsen, et al.,Psychopharmacology, 101, 56-61 (1990).
Millan, et al.,Eur. J. Pharmacol, 325, 9-12 (1997).
Millan, et al.,J. Pharmacol. Exp. Ther., 298 (2), 581-591 (2001).
Shih, et al.,Brain Research, 835, 104-112 (1999).
Koskinen, et al.,Pharmacol. Biochem. Behav., 66(4), 729-738 (2000).
Fox, et al.,Drug News Perspect., 12(8), 477-483 (1999).
Smith, et al.,J. Psychopharmacol., 6(3), 376-381 (1992).
Millan, et al.,Eur. J. Neurosci, 12, 1079-95 (2000).
DeBoer, et al.,J. Pharmacol. Exp. Ther., 277(2), 852-60 (1997).
Haddjeri, et al.,Naunyn-Schmiedeberg's Archiv. Pharmacol., 355(1), 20-9 (1997).
Nutt,J. Psychopharmacol., 8(4), 193-195 (1994).
Lindstrom,Trends Pharmacol. Sci., 21(6), 198-199 (2000).
Millan, et al.,J. Pharmacol. Exp. Ther., 292(1), 54-66 (2000).
Cussac, et al.,Nauyn-Schmiedeberg's Arch. Pharmacol., 361(2), 549-54 (2000).
Reavill, et al.,Br. J. Pharmacol., 126(3), 572-574 (1999).
Gobert, et al.,Synapse, 36(3), 205-221 (2000).
Lane,J. Pyschopharmacol., 11(1), 72-82 (1997).
O'Neill, et al.,Pharmacology, Biochemistry and Behavior, 1999, 63, 237-243.
Reavill, et al.,British Journal of Psychopharmacology, 1999, 126, 572-574.
Herrick-Davis, et al.,Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 226-232.
Wood, et al.,Drug Development Research, 2001, 54, 88-94.
Paiva, et al.,Psychopharmacology, 1988, 96, 395-399.
Dugovic,Journal Sleep Research, 1992, 1, 1163-1168.
Landolt, et al.,Neuropsychopharmacology, 1999, 21, 455-466.
Sharpley, et al.,Biological Psychiatry, 2000, 47, 468-470.
Foreman, et al.,Life Sciences, 1989, 45, 1263-1270.
Klint, et al.,Psychopharmacology, 1995, 119, 291-294.
Hirschfeld,Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
Popova, et al.,Neuroendocrinology, 2002, 76, 28-34.
McMahon, et al.,Journal of Neuroscience, 2001, 21, 7781-7787.
Filip, et al.,Pharmacology, Biochemistry and Behaviour, 2002, 71, 545-756.
Fox, et al.,Drug News and Perspectives, 1999, 12:477-483.
Fox, et al.,Movement Disorders, 2000, 15:1064-1069.
Berendsen, et al.,Psychopharmacology, 1990, 101, 57-61.
Millan, et al.,European Journal of Pharmacology, 1997, 325, 9-12.
Koskinin, et al.,Pharmacology, Biochemistry and Behaviour, 2000, 66, 729-738.
White, et al.,Pharmacology, Biochemistry and Behaviour, 1991, 39, 729-736.
Millan, et al.,Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 581-591.
Mundo, et al.,International Clinical Psychopharmacology, 2000, 15, 69-76.
Sara, et al.,Behavioural Neural Biology, 1989, 51, 401-411.
Smith, et al.,Journal of Psychopharmacology, 1992, 6, 376-381.
Coull, et al.,Psychopharmacology, 1996, 123, 239-249.
Telles, et al.,European Journal of Pharmacology, 1995, 277, 113-116.
Haapalinna, et al.,European Journal of Pharmacology, 1998, 347, 29-40.
“Dexefaroxan, efaroxan, L-0046, RX-821037”,Pharmaproject, Phase II Clinical Trial (2005).
Nutt,J. Psychopharmacology, 1994, 8, 193-195.
Litman, et al.,British Journal of Psychiatry, 1996, 168, 571-579.
Hertel, et al.,Science, 1999, 286, 105-107.
“Idazoxan, CGP-25811A, LOO22, RX-781094”,Pharmaproject, Phase II Clinical Trial (2005).
“Fipamezol, JP-1730”,Pharmaproject, Phase II Clinical Trial (2005).
Grondin, et al.,Naunyn Schmiedebergs Archives of Pharmacology, 2000, Feb:361, 181-186.
Rascol, et al.,Mov. Disord., 2001, 16, 708-713.
Brown, et al.,Investigational Drugs, 2002, 5, 454-468.
Clark, et al.,Neuroendocrinology, 1985, 41, 36-43.
Reid, et al.,Lancet, 1987, 22, (8556):421-423.
Koskinen, et al.,Physiology and Behaviour, 1991, 50, 589-593.
Kunelius, et al.,Urology, 1997, 49, 441-444.
Brocco Mauricette
Dekeyne Anne
Lavielle Gilbert
Millan Mark
Muller Olivier
Hueschen and Sage
Les Laboratoires Servier
Richter Johann
Sackey Ebenezer
LandOfFree
Diphenylurea compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylurea compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylurea compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3597113